Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03092375 · ClinicalTrials.gov registry record · Phase 3
Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects
A Phase 3 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 3
- Development phase
- 177
- Enrollment target
NCT03092375 is a Phase 3 study that has completed, run by University of Florida. The registered enrollment target is 177 participants.
The verdict
NCT03092375, a Phase 3 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 177 participants
- Enrollment target
Study Summary
The study will enroll well-compensated cirrhotic as well as non-cirrhotic subjects treatment experienced with an NS5a Inhibitor + sofosbuvir and will include patients who did not complete the prescribed duration due to adverse event or any reason other than for non/poor compliance. Subjects will be randomized to 12 or 16 weeks of treatment.
Interventions
- DRUG Glecaprevir/Pibrentasvir (G/P) 300mg/120mg
- DRUG Ribavirin 200Mg Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2017-04-20 |
| Est. Completion | 2020-02-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03092375
The ClinicalTrials.gov registry entry for NCT03092375 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glecaprevir/Pibrentasvir (G/P) 300mg/120mg is the first listed.
NCT03092375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03092375 about?
NCT03092375 is a clinical study titled "Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects". The study will enroll well-compensated cirrhotic as well as non-cirrhotic subjects treatment experienced with an NS5a Inhibitor + sofosbuvir and will include patients who did not complete the prescribed duration due to adverse event or any reason other than for non/poor compliance. Subjects will be ...
What is the current status of trial NCT03092375?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 177 participants. The study started on 2017-04-20. Estimated completion is 2020-02-06.
What interventions are being tested in trial NCT03092375?
The interventions under investigation include: Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (DRUG), Ribavirin 200Mg Tablet (DRUG).
Who is sponsoring clinical trial NCT03092375?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.